Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pandect Bioventures, founded in 2016 and based in South San Francisco, California, specializes in funding and supporting early-stage biotech and pharmaceutical companies. The firm operates a 40,000 square foot incubator facility that provides essential resources and operational support to its portfolio companies. This integrated approach allows Pandect to assist entrepreneurs in achieving critical business milestones while driving innovation in healthcare.
The firm has established itself as a significant player in the biotech sector, focusing on seed and Series A investments. Pandect Bioventures has a concentrated portfolio of five companies, reflecting its commitment to high-touch, hands-on involvement in the development of its investments. The firm leverages exclusive relationships with research institutions to access emerging discoveries and intellectual property, enhancing its investment strategy.
Pandect Bioventures invests primarily in early-stage healthcare innovations, particularly within the biotech and pharmaceutical sectors. The firm targets companies at the seed and Series A stages, employing a rigorous assessment process to evaluate investment opportunities. This thorough approach ensures that they select ventures with strong potential for growth and innovation.
Investment checks typically range from seed funding to Series A, allowing for flexibility in supporting startups as they scale. Pandect's unique incubator model provides portfolio companies with access to state-of-the-art research facilities and technical advisory support. This infrastructure is designed to help entrepreneurs navigate the complexities of bringing their innovations to market effectively.
Pandect Bioventures has invested in a select group of five notable companies, each focusing on innovative solutions in the healthcare sector:
This concentrated portfolio reflects Pandect's strategy of providing high-touch support to its companies, ensuring they have the resources needed to succeed in the competitive biotech landscape.
Walter H. Moos, Ph.D. - Managing Director and Co-Founder. Walter has a background as the former President of SRI Biosciences and has held a VP position at SRI International. He is a well-established figure in the San Francisco Bay biotech community.
Mohamad Tabrizi, MBA - Managing Director. Mohamad brings extensive experience in venture capital and operational management within the biotech sector.
Michael X. Hui, MBA - Managing Director. Michael has a strong background in investment management and has been involved in various successful biotech ventures.
Linda Maduwura - CFO. Linda oversees the financial operations of the firm, ensuring sound fiscal management and strategic financial planning.
David Spellmeyer, Ph.D. - Executive in Residence. David has significant experience in drug development and regulatory affairs, providing valuable insights to portfolio companies.
Krishna Kodukula, Ph.D. - Executive in Residence. Krishna specializes in biotechnology and pharmaceuticals, offering expertise in scientific research and development.
Robert Wild, Ph.D. - Executive in Residence. Robert has a strong background in biopharmaceuticals and provides strategic guidance to portfolio companies.
Robert Lutz, Ph.D. - Executive in Residence. Robert brings extensive experience in drug discovery and development, contributing to the operational support of portfolio companies.
To pitch Pandect Bioventures, founders should visit their website at pandectbio.com. The firm does not specify a preferred channel for submissions, but the website serves as the primary point of contact for applications. Founders should include a clear overview of their business model, market opportunity, and any relevant data supporting their innovation. Response times may vary, so patience is advised after submission.
As of 2023, Pandect Bioventures continues to focus on its investment strategy in the biotech sector, with a portfolio that includes five active companies. The firm has not publicly disclosed any recent exits or new fund raises, indicating a concentrated investment approach.
In 2021, Pandect Bioventures invested in Walking Fish Therapeutics, which specializes in B cell medicines and cell-based therapeutics. This investment aligns with their focus on innovative healthcare solutions.
In 2020, the firm made significant investments in Circle Pharma and Walden Biosciences, both of which are developing groundbreaking treatments in oncology and kidney disease, respectively.
What are Pandect Bioventures' investment criteria?
Pandect Bioventures focuses on early-stage biotech and pharmaceutical companies, particularly those at the seed and Series A stages. They look for innovative healthcare solutions with strong potential for growth and market impact.
How can I pitch to Pandect Bioventures?
Founders interested in pitching to Pandect Bioventures can visit their website at pandectbio.com. While specific email addresses are not provided, the website serves as the primary channel for applications and inquiries.
What makes Pandect Bioventures different from other investors?
Pandect Bioventures combines capital investment with hands-on operational support through its 40,000 square foot incubator facility. This integrated approach allows them to provide tailored assistance to portfolio companies, enhancing their chances of success.
What is the geographic focus of Pandect Bioventures?
The firm primarily invests in companies based in the United States, particularly those located in biotech hubs like South San Francisco.
What is the typical check size for investments?
While specific check sizes are not disclosed, Pandect Bioventures invests in early-stage companies, typically at the seed and Series A stages, which suggests a range that aligns with early funding rounds.
What kind of post-investment support does Pandect Bioventures provide?
Pandect offers extensive operational support, including access to their incubator facilities, technical advisory services, and strategic guidance from experienced industry professionals. This support is designed to help portfolio companies achieve critical business milestones.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.